NeoMatrix: A “Pap Smear for Breast Cancer”
Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
MicroTransponder is developing a wireless neurostimulation device for the treatment of chronic pain.
Sword Diagnostics of Illinois has developed a “next-generation” system to increase the sensitivity (and therefore accuracy) of diagnostic tests.
There’s one change that women don’t always discuss with their gynecologists.
Jaleva’s Stayzon technology utilizes a specific formulation of resins that is designed to keep medication in place for up to 96 hours and provide extended-release drug delivery to the skin.
LAMP (Lysosome-Associated Membrane Protein) is a gene that has been shown to enhance immune response when incorporated into a DNA vaccine.
Intravenous (IV) drugs leave a huge margin for human error, particularly at the point of administration.
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
The company’s first product is a low-profile “Stent-On-a-Wire” system that reduces the number of steps involved in the stenting procedure.
Copyright © 2024 | WordPress Theme by MH Themes